Regend Therapeutics
Privately held: no public share price · China
Assets
(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Airway epithelial regeneration (autologous basal cells)Cell therapy | Chronic Obstructive Pulmonary Disease | |
| Phase 1 | Renal progenitor cell therapyCell therapy | Type 2 DiabetesChronic Kidney Disease | |
| Phase 1 | Airway basal layer stem cellsCell therapy | Chronic Obstructive Pulmonary Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
No financial reports recorded.